IN ANCA-ASSOCIATED VASCULITIS
TAVNEOS has received European Commission approval and will receive marketing authorization in all member states of the European Union, as well as in Iceland, Liechtenstein and Norway.
TAVNEOS, a novel therapy for GPA/MPA that selectively targets
C5aR to achieve and sustain remission while reducing GC use1-3
TAVNEOS, in combination with rituximab or cyclophosphamide, is indicated for the treatment of adult patients with severe, active granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA).1
TAVNEOS should be initiated and monitored by healthcare professionals experienced in the diagnosis and treatment of GPA or MPA1
Product availability may vary by country. Sign up here to receive information when TAVNEOS is available in your marketSign up here